AntriaBio raises $6.7M, plans to file new drug application
LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.
The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.
AntriaBio did not return requests for comment.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.
In early May, AntriaBio launched the first in-human study of AB101. The company said it plans to file a new drug application with the FDA this month.
LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.
The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.
AntriaBio did not return requests for comment.
The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.
In early May, AntriaBio launched the…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
